Zhenhua Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhenhua Wu has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
Anchen Ma
Terahertz Research Center, School of Electronic Science and Engineering, University of Electronic Science and Technology of China, Cooperative Innovation Centre of Terahertz Science,Chengdu,P.R. China,610054
1 shared publication- Andrew Hastie
GSK, Rockville, MD, USA
1 shared publication - Anne Schuind
GSK, Rockville, MD, USA
1 shared publication - Anthony Lawrence Cunningham
The Westmead Institute for Medical Research, University of Sydney, Sydney, Australia
1 shared publication - Bin Gu
Questrom School of Business, Boston University, Boston, Massachusetts 02215
1 shared publication - Bo Wang
The Cooperative Innovation Center of Terahertz Science, University of Electronic Science and Technology of China, Chengdu, 610054, China
1 shared publication
Latest Publications
- Open Access
- 1 August 2023
- Published by Academy of Management in Academy of Management Proceedings
- Vol. 2023 (1)
Investor Attention and Crowdfunding Performance
- 1 August 2023
- Published by Academy of Management in Academy of Management Proceedings
- Vol. 2023 (1)
Open AccessInvestor Attention and Crowdfunding Performance
- Open Access
- 21 August 2022
- Published by Wiley in Physica Status Solidi (a)
- Vol. 219 (16)
Interfacial‐Modulated Growth of Nanostructured Bi2Te3 Films for Enhancing Thermoelectric Performance
- 21 August 2022
- Published by Wiley in Physica Status Solidi (a)
- Vol. 219 (16)
Open AccessInterfacial‐Modulated Growth of Nanostructured Bi2Te3 Films for Enhancing Thermoelectric Performance
- Open Access
- 2 August 2022
- Published by Elsevier in Chemical Engineering Journal
- Vol. 450, 138446
Covalent organic networks for in situ entrapment of enzymes with superior robustness and durability
- 2 August 2022
- Published by Elsevier in Chemical Engineering Journal
- Vol. 450, 138446
Open AccessCovalent organic networks for in situ entrapment of enzymes with superior robustness and durability
- 1 August 2022
- Published by American Scientific Publishers in Journal of Biomaterials and Tissue Engineering
- Vol. 12 (8) , 1588-1593
Effects of Adrenomedullin (ADM)-Modified Bone Marrow Mesenchymal Stem Cells (BMSCs) Transplantation on Cardiac Function and Matrix Metalloproteinase Levels in Rats with Heart Failure
After ADM gene treatment, bone marrow mesenchymal stem cells (BMSCs) were transplanted into rats with heart failure to study its effect on rat heart function and matrix metalloproteinases (MMPs) expression. The rats were assigned into control group, BMSCs group and ADM group. 4 weeks after transplantation, the rats’ cardiac function indexes were detected and the levels of MMP-2 and MMP-9 was measured by western blot. Echocardiography analysis showed significant differences between groups (except LVDd) (P < 0.05). BMSCs and ADM groups had significantly lower LVEF and LVFS levels than control group (P < 0.05) with a significantly higher level in ADM group than BMSCs group (P < 0.05). However, BMSCs and ADM groups presented a significantly higher LVDs (P < 0.05) without difference between them (P > 0.05). Interestingly, no difference of LVDd was found among groups (P > 0.05). MMP-2 and MMP-9 levels in BMSCs group were 0.389±0.021, 0.512±0.018, respectively, which were significantly elevated compared to control group (P < 0.05); MMP-2 and MMP-9 protein level in the ADM group was 0.440±0.018 and 0.539±0.032 respectively, which was significantly higher than control group (P < 0.05). Compared with BMSCs group, ADM group had significantly increased protein levels of MMP-2/9 (P < 0.05). In conclusion, ADM-modified BMSCs transplantation can significantly inhibit MMP-2 and MMP-9 level, thereby improving the heart function of rats with heart failure.
- 1 August 2022
- Published by American Scientific Publishers in Journal of Biomaterials and Tissue Engineering
- Vol. 12 (8) , 1588-1593
Effects of Adrenomedullin (ADM)-Modified Bone Marrow Mesenchymal Stem Cells (BMSCs) Transplantation on Cardiac Function and Matrix Metalloproteinase Levels in Rats with Heart Failure
After ADM gene treatment, bone marrow mesenchymal stem cells (BMSCs) were transplanted into rats with heart failure to study its effect on rat heart function and matrix metalloproteinases (MMPs) expression. The rats were assigned into control group, BMSCs group and ADM group. 4 weeks after transplantation, the rats’ cardiac function indexes were detected and the levels of MMP-2 and MMP-9 was measured by western blot. Echocardiography analysis showed significant differences between groups (except LVDd) (P < 0.05). BMSCs and ADM groups had significantly lower LVEF and LVFS levels than control group (P < 0.05) with a significantly higher level in ADM group than BMSCs group (P < 0.05). However, BMSCs and ADM groups presented a significantly higher LVDs (P < 0.05) without difference between them (P > 0.05). Interestingly, no difference of LVDd was found among groups (P > 0.05). MMP-2 and MMP-9 levels in BMSCs group were 0.389±0.021, 0.512±0.018, respectively, which were significantly elevated compared to control group (P < 0.05); MMP-2 and MMP-9 protein level in the ADM group was 0.440±0.018 and 0.539±0.032 respectively, which was significantly higher than control group (P < 0.05). Compared with BMSCs group, ADM group had significantly increased protein levels of MMP-2/9 (P < 0.05). In conclusion, ADM-modified BMSCs transplantation can significantly inhibit MMP-2 and MMP-9 level, thereby improving the heart function of rats with heart failure.
- 1 June 2022
- Published by Elsevier in Chinese Chemical Letters
- Vol. 33 (6) , 3188-3192
Multiple exosome RNA analysis methods for lung cancer diagnosis through integrated on-chip microfluidic system
- 1 June 2022
- Published by Elsevier in Chinese Chemical Letters
- Vol. 33 (6) , 3188-3192
Multiple exosome RNA analysis methods for lung cancer diagnosis through integrated on-chip microfluidic system
- 2 December 2021
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 111 (4) , 1142-1151
Physicochemical and Functional Characterization of HS016, a Biosimilar of Adalimumab (Humira)
- 2 December 2021
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 111 (4) , 1142-1151
Physicochemical and Functional Characterization of HS016, a Biosimilar of Adalimumab (Humira)
- Open Access
- 1 December 2021
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 14, 10117-10129
Construction of a Ferroptosis-Related Gene Signature for Head and Neck Squamous Cell Carcinoma Prognosis Prediction
Background: Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignant cancers, and few studies have demonstrated the value of ferroptosis-related genes in prognosis. Methods: The original counts of RNA sequencing data and clinicopathological data were obtained from TCGA and GSE65858 datasets. Common ferroptosis-related genes related to prognosis were identified from the training set and were included in LASSO to determine the best prognosis. To evaluate the efficacy, time-dependent ROC and Kaplan–Meier (KM) survival analyses were applied. Moreover, univariate and multivariate Cox regression analyses were used to screen independent parameters of prognosis and build a nomogram. Eventually, possible biological pathways were proposed based on GSEA. Results: Among 242 ferroptosis-related genes, we identified that the FLT3, IL6, Keap1, NQO1, SOCS1 and TRIB3 genes were significantly connected with HNSCC patient prognosis as a six-gene signature. After, the patients were divided into high- and low-risk groups based on the six-gene signature. The KM survival curves demonstrated that the high-risk group had worse OS (p < 0.0001) and higher AUC values (0.654, 0.735, and 0.679 for 1-, 3-, and 5-year survival, respectively) for the prognostic signature of the six genes compared with other genes, which were also validated in the GSE65858 dataset. Moreover, GSEA suggested that the epithelial mesenchymal transition pathway was abundant and that the mesenchymal status in the high-risk group was substantially higher than that in the low-risk group. Finally, the immune microenvironment and differences in the content of immune cell types were demonstrated. Conclusion: We established a six-ferroptosis-related-gene model crossing clinical prognostic parameters that can predict HNSCC patient prognosis and provide a reliable prognostic evaluation tool to assist clinical treatment decisions.
- 1 December 2021
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 14, 10117-10129
Open AccessConstruction of a Ferroptosis-Related Gene Signature for Head and Neck Squamous Cell Carcinoma Prognosis Prediction
Background: Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignant cancers, and few studies have demonstrated the value of ferroptosis-related genes in prognosis. Methods: The original counts of RNA sequencing data and clinicopathological data were obtained from TCGA and GSE65858 datasets. Common ferroptosis-related genes related to prognosis were identified from the training set and were included in LASSO to determine the best prognosis. To evaluate the efficacy, time-dependent ROC and Kaplan–Meier (KM) survival analyses were applied. Moreover, univariate and multivariate Cox regression analyses were used to screen independent parameters of prognosis and build a nomogram. Eventually, possible biological pathways were proposed based on GSEA. Results: Among 242 ferroptosis-related genes, we identified that the FLT3, IL6, Keap1, NQO1, SOCS1 and TRIB3 genes were significantly connected with HNSCC patient prognosis as a six-gene signature. After, the patients were divided into high- and low-risk groups based on the six-gene signature. The KM survival curves demonstrated that the high-risk group had worse OS (p < 0.0001) and higher AUC values (0.654, 0.735, and 0.679 for 1-, 3-, and 5-year survival, respectively) for the prognostic signature of the six genes compared with other genes, which were also validated in the GSE65858 dataset. Moreover, GSEA suggested that the epithelial mesenchymal transition pathway was abundant and that the mesenchymal status in the high-risk group was substantially higher than that in the low-risk group. Finally, the immune microenvironment and differences in the content of immune cell types were demonstrated. Conclusion: We established a six-ferroptosis-related-gene model crossing clinical prognostic parameters that can predict HNSCC patient prognosis and provide a reliable prognostic evaluation tool to assist clinical treatment decisions.
- 23 October 2021
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-7
Completion of Global Navigation Satellite System Missing Data Based on Bidirectional Recurrent Neural Network
In fight test, Global Navigation Satellite System (GNSS) data missing inevitably in GNSS data recording attribute to such factors as satellite anomalies, follow-up reject of gross errors and so on. It has serious effects on the data correlation, principle component analysis and spectral analysis. Thus it is significant to fill missing values by interpolation method in the GNSS time series of aircraft. The research result of time series interpolation problem has already rich but time serious methods frequently-used such as traditional interpolation method, empirical Orthogonal Function and Singular Spectrum Analysis still have some disadvantages: For example, local feature fitting of the time series is not very good or the conditions of appliance is so harsh that it is hard to application and extension and It is easy to cause artificial distortion of the reconstructed time series. The article has presented a way of filling missing GNSS values of aircraft based on bidirectional recurrent neural network. Experiments in the article are carried out with samples from the complete time series of a plane throughout the year. Then we trained the bidirectional recurrent neural network and used the interpolation method to complete some groups missing GNSS values that missing time is three minutes, six minutes, nine minutes, twelve minutes, fifteen minutes respectively. Finally, the accuracy and validity of the experimental model used for completing the time seriously by interpolation method are verified.
- 23 October 2021
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-7
Completion of Global Navigation Satellite System Missing Data Based on Bidirectional Recurrent Neural Network
In fight test, Global Navigation Satellite System (GNSS) data missing inevitably in GNSS data recording attribute to such factors as satellite anomalies, follow-up reject of gross errors and so on. It has serious effects on the data correlation, principle component analysis and spectral analysis. Thus it is significant to fill missing values by interpolation method in the GNSS time series of aircraft. The research result of time series interpolation problem has already rich but time serious methods frequently-used such as traditional interpolation method, empirical Orthogonal Function and Singular Spectrum Analysis still have some disadvantages: For example, local feature fitting of the time series is not very good or the conditions of appliance is so harsh that it is hard to application and extension and It is easy to cause artificial distortion of the reconstructed time series. The article has presented a way of filling missing GNSS values of aircraft based on bidirectional recurrent neural network. Experiments in the article are carried out with samples from the complete time series of a plane throughout the year. Then we trained the bidirectional recurrent neural network and used the interpolation method to complete some groups missing GNSS values that missing time is three minutes, six minutes, nine minutes, twelve minutes, fifteen minutes respectively. Finally, the accuracy and validity of the experimental model used for completing the time seriously by interpolation method are verified.
- Open Access
- 1 October 2021
- Published by IOP Publishing in IOP Conference Series: Earth and Environmental Science
- Vol. 861 (4) , 042106
Loading rate effect on fracture process in Brazilian splitting tests of Beishan granites
- 1 October 2021
- Published by IOP Publishing in IOP Conference Series: Earth and Environmental Science
- Vol. 861 (4) , 042106
Open AccessLoading rate effect on fracture process in Brazilian splitting tests of Beishan granites
- Open Access
- 19 February 2021
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (7) , 2050-2057
The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials
In two large clinical trials (ZOE-50 [NCT01165177] and ZOE-70 [NCT01165229]), two doses of the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy (VE) against herpes zoster (HZ) in adults ≥50 years of age (YOA). This post-hoc analysis assessed the VE against HZ and postherpetic neuralgia (PHN), in participants from Asian study sites enrolled in ZOE-50/70. Reactogenicity and safety were also assessed. Participants ≥50 YOA were randomized 1:1 to receive 2 doses of either RZV or placebo, 2 months apart. VE was evaluated for a median follow-up of 4 years post-vaccination overall and by age in the ZOE-50 Asian population ≥50 YOA and in the pooled ZOE-50/70 Asian population ≥70 YOA. Of the 2,729 participants included in the ZOE-50 Asian population ≥50 YOA, 3 RZV and 66 placebo recipients reported a confirmed HZ episode. Overall VE was 95.6% (95% confidence interval [CI]: 86.4–99.1) against HZ and 100% (95% CI: 35.44–100) against PHN. In the pooled ZOE-50/70 Asian population ≥70 YOA, 4 RZV and 75 placebo recipients out of the 2,723 participants reported a confirmed HZ episode. Overall VE was 94.7% (95% CI: 85.9–98.6) against HZ and 89.8% (95% CI: 28.39–99.77) against PHN. Pain and myalgia were the most frequent solicited local and general adverse events, respectively, in both populations. No safety concern was identified during the study periods. RZV is highly efficacious against HZ and PHN and has an acceptable safety profile in Asian populations ≥50 YOA, similar to what was observed in the general ZOE-50/70 populations. Trademark statement: Shingrix is a trademark owned by or licensed to the GSK group of companies. What is the context? What is new? What is the impact?
- 19 February 2021
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (7) , 2050-2057
Open AccessThe adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials
In two large clinical trials (ZOE-50 [NCT01165177] and ZOE-70 [NCT01165229]), two doses of the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy (VE) against herpes zoster (HZ) in adults ≥50 years of age (YOA). This post-hoc analysis assessed the VE against HZ and postherpetic neuralgia (PHN), in participants from Asian study sites enrolled in ZOE-50/70. Reactogenicity and safety were also assessed. Participants ≥50 YOA were randomized 1:1 to receive 2 doses of either RZV or placebo, 2 months apart. VE was evaluated for a median follow-up of 4 years post-vaccination overall and by age in the ZOE-50 Asian population ≥50 YOA and in the pooled ZOE-50/70 Asian population ≥70 YOA. Of the 2,729 participants included in the ZOE-50 Asian population ≥50 YOA, 3 RZV and 66 placebo recipients reported a confirmed HZ episode. Overall VE was 95.6% (95% confidence interval [CI]: 86.4–99.1) against HZ and 100% (95% CI: 35.44–100) against PHN. In the pooled ZOE-50/70 Asian population ≥70 YOA, 4 RZV and 75 placebo recipients out of the 2,723 participants reported a confirmed HZ episode. Overall VE was 94.7% (95% CI: 85.9–98.6) against HZ and 89.8% (95% CI: 28.39–99.77) against PHN. Pain and myalgia were the most frequent solicited local and general adverse events, respectively, in both populations. No safety concern was identified during the study periods. RZV is highly efficacious against HZ and PHN and has an acceptable safety profile in Asian populations ≥50 YOA, similar to what was observed in the general ZOE-50/70 populations. Trademark statement: Shingrix is a trademark owned by or licensed to the GSK group of companies. What is the context? What is new? What is the impact?